Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTAN6JD)

• DTT Name: Glutamate receptor AMPA (GRIA)
• Synonyms: Glutamate receptor ionotropic, AMPA; Glutamate receptor; AMPA selective glutamate receptor; AMPA receptor
• Gene Name: NO-GeName
• DTT Type: Successful target; [1]
• Related Disease:
  Alzheimer disease [ICD-11: 8A20]
  Anxiety disorder [ICD-11: 6B00-6B0Z]
  Appearance/behaviour symptom [ICD-11: MB23]
  Corneal disease [ICD-11: 9A76-9A78]
  Depression [ICD-11: 6A70-6A7Z]
  Insomnia [ICD-11: 7A00-7A0Z]
  Malaria [ICD-11: 1F40-1F45]
  Monitored anaesthesia care [ICD-11: N.A.]
  Neuropathy [ICD-11: 8C0Z]
  Pediculosis [ICD-11: 1G00]
  Substance abuse [ICD-11: 6C40]
• BioChemical Class: Chloride channel
• UniProt ID: NOUNIPROTAC
• TTD ID: T54128

Molecular Interaction Atlas (MIA) of This DTT

16 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acamprosate	DMO381I	Alcohol dependence	6C40.2	Approved	[2]
Aprobarbital	DMOWK6B	Anaesthesia	9A78.6	Approved	[3]
Artemisinin SP	DMFETDK	Malaria	1F40-1F45	Approved	[4]
Barbiturate	DMJIA6T	Anaesthesia	9A78.6	Approved	[5]
Bromazepam	DMY9TCW	Anxiety disorder	6B00-6B0Z	Approved	[6]
Desflurane	DM2TO9R	Anaesthesia	9A78.6	Approved	[7]
Dihydroergotoxine	DM5D6WZ	Alzheimer disease	8A20	Approved	[8]
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[9]
Enflurane	DM0YJSB	Anaesthesia	9A78.6	Approved	[10]
Fospropofol disodium	DMKLJRD	Monitored anaesthesia care	N.A.	Approved	[11]
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[12]
Heptabarbital	DMOB2F3	Anaesthesia	9A78.6	Approved	[13]
Isoflurane	DMY6T31	Anaesthesia	9A78.6	Approved	[14], [15]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[16]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[17]
Zopiclone	DMPI6Z0	Insomnia	7A00-7A0Z	Approved	[1], [18], [19]

18 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
FASORACETAM	DM8E51L	Cognitive impairment	6D71	Phase 3	[11]
CX-516	DMSR7D2	Pervasive developmental disorder	6A00-6A0Z	Phase 2/3	[20]
BIIB104	DMJBDL0	Cognitive impairment	6D71	Phase 2a	[21]
AZD7325	DMXF26Y	Anxiety disorder	6B00-6B0Z	Phase 2	[22]
Coluracetam	DMI2GSK	Alzheimer disease	8A20	Phase 2	[23]
CX-1739	DMJD7H4	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[24]
CX-717	DMM65W1	Spinal cord injury	ND51.2	Phase 2	[25]
CX1789	DMA5D6T	Obstructive sleep apnea	7A41	Phase 2	[26]
Mibampator	DME5CSV	Alzheimer disease	8A20	Phase 2	[27]
PF-04958242	DMRAFBK	Schizophrenia	6A20	Phase 2	[21]
Selurampanel	DMJH6EL	Epilepsy	8A60-8A68	Phase 2	[28]
TAK-653	DMNB4P1	Depression	6A70-6A7Z	Phase 2	[21]
Talampanel	DMJOM5L	Parkinson disease	8A00.0	Phase 2	[29], [30], [31]
TRO-19622	DMMQYF6	Peripheral neuropathy	8C0Z	Phase 2	[32]
AZD-8418	DM9X20P	Schizophrenia	6A20	Phase 1	[33]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[34]
TAK-137	DMYG704	Psychiatric disorder	6E8Z	Phase 1	[11]
ZK-200775	DM2LHPU	Coronary artery disease	BA80	Phase 1	[35]

16 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Becampanel	DMPIJE7	Epilepsy	8A60-8A68	Discontinued in Phase 2	[30], [31]
ELB-139	DM0B23J	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 2	[31]
IPENOXAZONE	DM4WJDK	Alzheimer disease	8A20	Discontinued in Phase 2	[11]
S-18986	DMA01BV	Alzheimer disease	8A20	Discontinued in Phase 2	[31]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[36]
GSK729327	DMRTPY6	Schizophrenia	6A20	Discontinued in Phase 1	[37]
S-1746	DMRXB8F	Cerebrovascular ischaemia	8B1Z	Discontinued in Phase 1	[38]
ACEA-2085	DMXLB02	Pain	MG30-MG3Z	Terminated	[42]
GYKI-52466	DM3YG5P	Alzheimer disease	8A20	Terminated	[43]
GYKI-53655	DMC0JN8	N. A.	N. A.	Terminated	[44]
IDRA-21	DMG1FQW	Alzheimer disease	8A20	Terminated	[45]
L-698544	DMLRBN1	Alzheimer disease	8A20	Terminated	[46]
NS-257	DM9F81Z	Cerebrovascular ischaemia	8B1Z	Terminated	[47]
NS-377	DM2MU98	Alzheimer disease	8A20	Terminated	[48]
PNQX	DMT83V6	Cerebrovascular ischaemia	8B1Z	Terminated	[49]
Zonampanel	DM70HZD	N. A.	N. A.	Terminated	[36]

5 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIIR-777	DM2JOXF	Neurological disorder	6B60	Preclinical	[39]
CX-1501	DMKZCBE	Alzheimer disease	8A20	Preclinical	[40]
GYKI-47261	DM97RV4	Parkinson disease	8A00.0	Preclinical	[41]
TP-023	DM6W9YM	Anxiety disorder	6B00-6B0Z	Preclinical	[31]
TPT-43	DM06BUL	Alzheimer disease	8A20	Preclinical	[31]

16 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(S)-AMPA	DMNJSTM	Discovery agent	N.A.	Investigative	[50]
(S)-WILLARDIINE	DMXQ47M	Discovery agent	N.A.	Investigative	[51]
2-AMINO-3-(4-HYDROXY-1,2,5-OXADIAZOL-3-YL)PROPIONIC ACID (STRUCTURAL MIX)	DMQKGL3	Discovery agent	N.A.	Investigative	[52]
4,5,6,7-tetrahydroisoxazolo-[5,4-c]-pyridin-3-ol	DMO91EH	Discovery agent	N.A.	Investigative	[53]
7-chloro-3-hydroxyquinazoline-2,4-dione	DM3OMLU	Discovery agent	N.A.	Investigative	[54]
Bicuculline	DMA6VQW	Discovery agent	N.A.	Investigative	[55]
DNQX	DMQXPA5	Discovery agent	N.A.	Investigative	[56]
LY-314657	DMD2J97	Discovery agent	N.A.	Investigative	[57]
LY-392098	DM1KW0L	Cognitive impairment	6D71	Investigative	[58]
Muscimol	DMNTF2O	Discovery agent	N.A.	Investigative	[4]
N-(4-hydroxyphenylpropanyl)-spermine	DM4QR2C	Discovery agent	N.A.	Investigative	[59]
N-methylbicuculline	DM5GXIS	Discovery agent	N.A.	Investigative	[60]
Piriqualone	DM7XTHD	Discovery agent	N.A.	Investigative	[61]
RPR-118723	DMLDWCB	Discovery agent	N.A.	Investigative	[62]
[3H]CNQX	DMIFKUX	Discovery agent	N.A.	Investigative	[63]
[3H]kainate	DMMK7XU	Discovery agent	N.A.	Investigative	[64]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Alzheimer's disease	8A00.0	Entorhinal cortex	1.79E-04	-0.69	-0.58
Schizophrenia	6A20	Pre-frontal cortex	5.94E-02	-0.46	-0.15
Schizophrenia	6A20	Superior temporal cortex	8.64E-01	-0.52	-0.47
Coronary artery disease	BA80-BA8Z	Peripheral blood	7.03E-02	-0.32	-1.9
Parkinson's disease	8A00.0	Substantia nigra tissue	9.57E-01	-0.39	-0.21

References

• [1] Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
• [2] Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.
• [3] Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J Pharm Biomed Anal. 2002 Jun 1;28(5):903-8.
• [4] GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
• [5] Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
• [6] Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
• [7] Modulation of NMDA receptor function by ketamine and magnesium. Part II: interactions with volatile anesthetics. Anesth Analg. 2001 May;92(5):1182-91.
• [8] Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
• [9] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [10] Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [12] Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
• [13] A computer program using disposition decomposition analysis in pharmacodynamics. Biopharm Drug Dispos. 1997 Jan;18(1):9-15.
• [14] Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
• [15] Effects of GABAergic agents on anesthesia induced by halothane, isoflurane, and thiamylal in mice. Pharmacol Biochem Behav. 2002 May;72(1-2):111-6.
• [16] NMDA-induced seizure intensity is enhanced in COX-2 deficient mice. Neurotoxicology. 2008 Nov;29(6):1114-20.
• [17] Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
• [18] The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs. 2004;18 Suppl 1:9-15; discussion 41, 43-5.
• [19] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [20] Autism spectrum disorders: emerging pharmacotherapy. Expert Opin Emerg Drugs. 2005 Aug;10(3):521-36.
• [21] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [22] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [23] MKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated rats. J Neural Transm. 2008 Jul;115(7):1027-35.
• [24] AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013 Jan;64:268-82.
• [25] Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep. J Psychopharmacol. 2012 Aug;26(8):1047-57.
• [26] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [27] Mibampator (LY451395) Randomized Clinical Trial for Agitation/Aggression in Alzheimer's disease. Int Psychogeriatr. 2013 May; 25(5): 707-719.
• [28] BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Expert Opin Investig Drugs. 2014 Jan;23(1):107-13.
• [29] Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model. Epilepsia. 2009 Apr;50(4):694-701.
• [30] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [31] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [32] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [33] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031633)
• [34] Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil r... J Med Chem. 2007 Apr 5;50(7):1558-70.
• [35] Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. Bioorg Med Chem Lett. 2001 May 7;11(9):1205-10.
• [36] Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11.
• [37] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [38] 1,026 experimental treatments in acute stroke. Ann Neurol. 2006 Mar;59(3):467-77.
• [39] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [40] Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets. 2007 May;8(5):583-602.
• [41] Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
• [42] Interaction among NMDA receptor-, NMDA glycine site- and AMPA receptor antagonists in spinally mediated analgesia. Can J Anaesth. 2000 Jul;47(7):693-8.
• [43] New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):167-70.
• [44] Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J Med Chem. 1996 Jan 19;39(2):343-6.
• [45] IDRA-21, a positive AMPA receptor modulator, inhibits synaptic and extrasynaptic NMDA receptor mediated events in cultured cerebellar granule cells. Neuropharmacology. 2004 Jun;46(8):1105-13.
• [46] 3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J Med Chem. 1993 Oct 29;36(22):3397-408.
• [47] Characterization of the binding of [3H]NS 257, a novel competitive AMPA receptor antagonist, to rat brain membranes and brain sections. J Neurochem. 1995 Sep;65(3):1264-73.
• [48] In vivo and in vitro evaluation of AMPA receptor antagonists in rat hippocampal neurones and cultured mouse cortical neurones. Eur J Pharmacol. 1998 Jul 24;353(2-3):159-67.
• [49] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005697)
• [50] Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J Med Chem. 2005 Dec 1;48(24):7867-81.
• [51] Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J Med Chem. 1997 Oct 24;40(22):3645-50.
• [52] 4-hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological charact... J Med Chem. 2010 May 27;53(10):4110-8.
• [53] Reduction in potency of selective gamma-aminobutyric acidA agonists and diazepam in CA1 region of in vitro hippocampal slices from chronic flurazepam-treated rats. J Pharmacol Exp Ther. 1992 Jul;262(1):204-11.
• [54] Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
• [55] Effects of subcutaneous administration of the gamma-aminobutyric acid(A) receptor agonist muscimol on water intake in water-deprived rats. Physiol Behav. 2002 Nov;77(2-3):445-50.
• [56] Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
• [57] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [58] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4251).
• [59] Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands. Bioorg Med Chem. 2010 Feb 15;18(4):1381-7.
• [60] GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex. Br J Pharmacol. 2001 Oct;134(4):896-904.
• [61] Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antag... Bioorg Med Chem Lett. 2001 Jan 22;11(2):177-81.
• [62] Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
• [63] Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists. J Med Chem. 2006 Apr 20;49(8):2579-92.
• [64] 1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of pot... J Med Chem. 2008 Oct 23;51(20):6614-8.